David Grayzel

David Grayzel is a Partner at Atlas Venture, where he focuses on creating and investing in novel therapeutics companies. An alumnus of Harvard Medical School and Stanford University, he has co-founded multiple biotech startups, including Q32 Bio and Vedere Bio, leveraging his extensive experience in clinical development and business operations.

With deep roots in the Boston area from his medical training at Harvard, residency at Mass General, and his entire venture career, David is embedded in the local community. This long-standing connection suggests a likely affinity for local culture and sports.

He served as the founding CEO of Q32 Bio, a company focused on autoimmune and inflammatory diseases which he co-founded at Atlas.